Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme
Top Cited Papers
- 15 July 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 13 (9), 974-982
- https://doi.org/10.1093/neuonc/nor077
Abstract
Glioblastoma multiforme (GBM) is the most common and aggressive brain cancer, and despite treatment advances, patient prognosis remains poor. During routine animal studies, we serendipitously observed that fenbendazole, a benzimidazole antihelminthic used to treat pinworm infection, inhibited brain tumor engraftment. Subsequent in vitro and in vivo experiments with benzimidazoles identified mebendazole as the more promising drug for GBM therapy. In GBM cell lines, mebendazole displayed cytotoxicity, with half-maximal inhibitory concentrations ranging from 0.1 to 0.3 µM. Mebendazole disrupted microtubule formation in GBM cells, and in vitro activity was correlated with reduced tubulin polymerization. Subsequently, we showed that mebendazole significantly extended mean survival up to 63% in syngeneic and xenograft orthotopic mouse glioma models. Mebendazole has been approved by the US Food and Drug Administration for parasitic infections, has a long track-record of safe human use, and was effective in our animal models with doses documented as safe in humans. Our findings indicate that mebendazole is a possible novel anti-brain tumor therapeutic that could be further tested in clinical trials.Keywords
This publication has 49 references indexed in Scilit:
- The microtubule inhibiting agent epothilone B antagonizes glioma cell motility associated with reorganization of the actin-binding protein α-actinin 4Oncology Reports, 2011
- Potent inhibition of tumoral hypoxia-inducible factor 1α by albendazoleBMC Cancer, 2010
- Evaluation of retinoic acid therapy for OTX2-positive medulloblastomasNeuro-Oncology, 2010
- Targeting protein kinases in central nervous system disordersNature Reviews Drug Discovery, 2009
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialThe Lancet Oncology, 2009
- Mutations in α-Tubulin Cause Abnormal Neuronal Migration in Mice and Lissencephaly in HumansCell, 2007
- β-Tubulin Genes from the Parasitic NematodeHaemonchus contortusModulate Drug Resistance inCaenorhabditis elegansJournal of Molecular Biology, 1995
- Bioavailability and tolerability of mebendazole in patients with inoperable hydatid diseaseTransactions of the Royal Society of Tropical Medicine and Hygiene, 1982
- Experience with mebendazole in the treatment of inoperable hydatid disease in EnglandTransactions of the Royal Society of Tropical Medicine and Hygiene, 1982
- Plasma concentrations of mebendazole during treatment of echinococcosisEuropean Journal of Clinical Pharmacology, 1980